FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039016871> ?p ?o ?g. }

• W2039016871 endingPage "2595" @default.
• W2039016871 startingPage "2591" @default.
• W2039016871 abstract "The combination of an oral fluoropyrimidine derivative, S‐1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer. This study was performed to determine the maximum tolerated dose (MTD) and recommended dose (RD) of irinotecan combined with S‐1 in a 3‐week cycle regimen and to observe the safety and efficacy for patients with previously untreated advanced colorectal cancer. Eighty milligrams per m 2 of S‐1 was given orally for 14 consecutive days and escalated doses of irinotecan were administered on days 1 and 8 every 3 weeks in the phase I trial. Forty patients were treated at the RD during the phase II trial. Forty‐three patients were enrolled between February 2005 and March 2007. The dose‐limiting toxicity was diarrhea and abdominal pain. The MTD of irinotecan was 100 mg/m 2 and the RD was determined to be 80 mg/m 2 of irinotecan combined with 80 mg/m 2 of S‐1. The phase II trial showed that 22 of 40 patients achieved a complete or partial response and eight had stable disease. The overall response rate was 55.0%. The median progression‐free survival time and median survival time were 6.7 and 21 months, respectively. There were no treatment‐related deaths. The main toxicities were leukopenia, neutropenia, anorexia and diarrhea. This study suggests the combination of irinotecan and S‐1 repeated every 3 weeks is tolerable and effective for patients with previously untreated advanced colorectal cancer. ( Cancer Sci 2010; 101: 2591–2595)" @default.
• W2039016871 created "2016-06-24" @default.
• W2039016871 creator A5000450244 @default.
• W2039016871 creator A5001341804 @default.
• W2039016871 creator A5007833906 @default.
• W2039016871 creator A5017008708 @default.
• W2039016871 creator A5026278665 @default.
• W2039016871 creator A5043272488 @default.
• W2039016871 creator A5051334674 @default.
• W2039016871 creator A5055212193 @default.
• W2039016871 creator A5057425915 @default.
• W2039016871 creator A5063624495 @default.
• W2039016871 creator A5070901487 @default.
• W2039016871 creator A5072512404 @default.
• W2039016871 creator A5080080439 @default.
• W2039016871 creator A5082136079 @default.
• W2039016871 creator A5083194761 @default.
• W2039016871 date "2010-09-24" @default.
• W2039016871 modified "2023-10-18" @default.
• W2039016871 title "Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer" @default.
• W2039016871 cites W141482010 @default.
• W2039016871 cites W1499419719 @default.
• W2039016871 cites W1968463676 @default.
• W2039016871 cites W1969825132 @default.
• W2039016871 cites W1973824708 @default.
• W2039016871 cites W2011679421 @default.
• W2039016871 cites W2012846370 @default.
• W2039016871 cites W2019908607 @default.
• W2039016871 cites W2037756952 @default.
• W2039016871 cites W2040401100 @default.
• W2039016871 cites W2044792687 @default.
• W2039016871 cites W2065064849 @default.
• W2039016871 cites W2069733373 @default.
• W2039016871 cites W2085705101 @default.
• W2039016871 cites W2096650733 @default.
• W2039016871 cites W2102172908 @default.
• W2039016871 cites W2110650955 @default.
• W2039016871 cites W2128447158 @default.
• W2039016871 cites W2133399075 @default.
• W2039016871 cites W2133671458 @default.
• W2039016871 cites W2138664319 @default.
• W2039016871 cites W2139248078 @default.
• W2039016871 cites W2152805228 @default.
• W2039016871 cites W2314927739 @default.
• W2039016871 cites W4237722346 @default.
• W2039016871 doi "https://doi.org/10.1111/j.1349-7006.2010.01728.x" @default.
• W2039016871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21077997" @default.
• W2039016871 hasPublicationYear "2010" @default.
• W2039016871 type Work @default.
• W2039016871 sameAs 2039016871 @default.
• W2039016871 citedByCount "9" @default.
• W2039016871 countsByYear W20390168712012 @default.
• W2039016871 countsByYear W20390168712013 @default.
• W2039016871 countsByYear W20390168712014 @default.
• W2039016871 countsByYear W20390168712021 @default.
• W2039016871 countsByYear W20390168712022 @default.
• W2039016871 crossrefType "journal-article" @default.
• W2039016871 hasAuthorship W2039016871A5000450244 @default.
• W2039016871 hasAuthorship W2039016871A5001341804 @default.
• W2039016871 hasAuthorship W2039016871A5007833906 @default.
• W2039016871 hasAuthorship W2039016871A5017008708 @default.
• W2039016871 hasAuthorship W2039016871A5026278665 @default.
• W2039016871 hasAuthorship W2039016871A5043272488 @default.
• W2039016871 hasAuthorship W2039016871A5051334674 @default.
• W2039016871 hasAuthorship W2039016871A5055212193 @default.
• W2039016871 hasAuthorship W2039016871A5057425915 @default.
• W2039016871 hasAuthorship W2039016871A5063624495 @default.
• W2039016871 hasAuthorship W2039016871A5070901487 @default.
• W2039016871 hasAuthorship W2039016871A5072512404 @default.
• W2039016871 hasAuthorship W2039016871A5080080439 @default.
• W2039016871 hasAuthorship W2039016871A5082136079 @default.
• W2039016871 hasAuthorship W2039016871A5083194761 @default.
• W2039016871 hasBestOaLocation W20390168711 @default.
• W2039016871 hasConcept C121608353 @default.
• W2039016871 hasConcept C126322002 @default.
• W2039016871 hasConcept C141071460 @default.
• W2039016871 hasConcept C2777063308 @default.
• W2039016871 hasConcept C2779802037 @default.
• W2039016871 hasConcept C2780259306 @default.
• W2039016871 hasConcept C2780873365 @default.
• W2039016871 hasConcept C2781413609 @default.
• W2039016871 hasConcept C29730261 @default.
• W2039016871 hasConcept C31760486 @default.
• W2039016871 hasConcept C526805850 @default.
• W2039016871 hasConcept C71924100 @default.
• W2039016871 hasConcept C90924648 @default.
• W2039016871 hasConceptScore W2039016871C121608353 @default.
• W2039016871 hasConceptScore W2039016871C126322002 @default.
• W2039016871 hasConceptScore W2039016871C141071460 @default.
• W2039016871 hasConceptScore W2039016871C2777063308 @default.
• W2039016871 hasConceptScore W2039016871C2779802037 @default.
• W2039016871 hasConceptScore W2039016871C2780259306 @default.
• W2039016871 hasConceptScore W2039016871C2780873365 @default.
• W2039016871 hasConceptScore W2039016871C2781413609 @default.
• W2039016871 hasConceptScore W2039016871C29730261 @default.
• W2039016871 hasConceptScore W2039016871C31760486 @default.
• W2039016871 hasConceptScore W2039016871C526805850 @default.
• W2039016871 hasConceptScore W2039016871C71924100 @default.

• next